Insider Selling: Clearmind Medicine (NASDAQ:CMND) Major Shareholder Sells $10,567.56 in Stock

Clearmind Medicine Inc. (NASDAQ:CMND) major shareholder Financial Lp Hrt sold 3,183 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $3.32, for a total value of $10,567.56. Following the completion of the transaction, the insider owned 103,492 shares in the company, valued at $343,593.44. This trade represents a 2.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Tuesday, June 16th, Financial Lp Hrt sold 22,139 shares of Clearmind Medicine stock. The stock was sold at an average price of $3.31, for a total value of $73,280.09.
• On Friday, June 12th, Financial Lp Hrt sold 2,102 shares of Clearmind Medicine stock. The stock was sold at an average price of $3.36, for a total value of $7,062.72.
• On Thursday, June 11th, Financial Lp Hrt sold 225,191 shares of Clearmind Medicine stock. The shares were sold at an average price of $0.12, for a total value of $27,022.92.
• On Wednesday, June 10th, Financial Lp Hrt purchased 2,159,052 shares of Clearmind Medicine stock. The stock was purchased at an average cost of $0.15 per share, with a total value of $323,857.80.

Clearmind Medicine Stock Performance

Shares of NASDAQ CMND opened at $3.07 on Friday. The business has a 50 day simple moving average of $5.36 and a 200 day simple moving average of $14.74. Clearmind Medicine Inc. has a 52 week low of $2.10 and a 52 week high of $524.00. The stock has a market cap of $3.13 million, a price-to-earnings ratio of -0.02 and a beta of 0.64.

Clearmind Medicine (NASDAQ:CMND) last issued its quarterly earnings data on Monday, June 15th. The company reported ($6.78) earnings per share for the quarter.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded shares of Clearmind Medicine from a “strong sell” rating to a “sell” rating in a report on Saturday.

About Clearmind Medicine

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.